PT-141 for Women: Sexual Wellness & Libido

PT-141 (bremelanotide) is the only peptide with FDA acknowledgment specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. Marketed as Vyleesi, it represents a fundamentally different approach to female sexual wellness — working through brain signaling rather than hormonal manipulation.

How PT-141 Works

PT-141 activates melanocortin-4 receptors (MC4R) in brain regions governing sexual arousal, including the medial preoptic area and ventromedial hypothalamus. This triggers downstream signaling cascades that enhance sexual desire and arousal through central nervous system pathways. Crucially, PT-141 does not alter estrogen, progesterone, or testosterone levels — avoiding the androgenic side effects (acne, hair growth, voice changes) associated with testosterone-based libido treatments.

Clinical Evidence

In phase 3 trials (RECONNECT program) enrolling over 1,200 premenopausal women, bremelanotide significantly increased the number of satisfying sexual events and reduced distress related to low desire compared to placebo. The FDA approved Vyleesi in June 2019 specifically for HSDD in premenopausal women.

Why PT-141 Over Hormonal Approaches

Testosterone cream/gel for female libido carries risks of androgenic side effects (facial hair, acne, deepening voice) and is not FDA-approved for women. Estrogen therapy addresses vaginal dryness but not desire. PT-141 is the only option that directly targets desire pathways without hormonal manipulation.

PT-141 is included in the Venus Protocol as the sexual wellness and libido pathway.